Handong Jiang

530 total citations
24 papers, 407 citations indexed

About

Handong Jiang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Handong Jiang has authored 24 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Handong Jiang's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Handong Jiang is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Handong Jiang collaborates with scholars based in China, Germany and United Kingdom. Handong Jiang's co-authors include Shan Xue, Wenjie You, Hui Qin, Xueqing Liu, Bi Chen, Huashi Guan, Zili Wang, Jieming Qu, Bi Chen and Xueqing Liu and has published in prestigious journals such as Scientific Reports, Cancer Letters and Signal Transduction and Targeted Therapy.

In The Last Decade

Handong Jiang

22 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Handong Jiang China 13 164 158 96 57 52 24 407
Shan Xue China 9 133 0.8× 133 0.8× 82 0.9× 43 0.8× 46 0.9× 28 353
Yajuan Zheng China 11 261 1.6× 164 1.0× 64 0.7× 68 1.2× 101 1.9× 16 493
Ju Ock Kim South Korea 10 170 1.0× 118 0.7× 106 1.1× 31 0.5× 38 0.7× 48 477
Elizabeth M. Park United States 8 401 2.4× 241 1.5× 62 0.6× 73 1.3× 102 2.0× 12 702
Xinyu Shao China 11 333 2.0× 179 1.1× 70 0.7× 122 2.1× 61 1.2× 29 585
Xia Yang China 9 214 1.3× 88 0.6× 59 0.6× 58 1.0× 47 0.9× 20 354
Cheng‐Bei Zhou China 9 329 2.0× 164 1.0× 86 0.9× 66 1.2× 81 1.6× 12 479
Maysam Mard‐Soltani Iran 11 175 1.1× 106 0.7× 48 0.5× 59 1.0× 72 1.4× 30 381
Naoko Ishida Japan 14 148 0.9× 161 1.0× 87 0.9× 75 1.3× 122 2.3× 39 515
Praveen Neeli United States 11 294 1.8× 127 0.8× 57 0.6× 77 1.4× 141 2.7× 23 541

Countries citing papers authored by Handong Jiang

Since Specialization
Citations

This map shows the geographic impact of Handong Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Handong Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Handong Jiang more than expected).

Fields of papers citing papers by Handong Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Handong Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Handong Jiang. The network helps show where Handong Jiang may publish in the future.

Co-authorship network of co-authors of Handong Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Handong Jiang. A scholar is included among the top collaborators of Handong Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Handong Jiang. Handong Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Xiaoping, Qiongfang Zha, Yu Kang, et al.. (2024). Diagnostic value of tumor markers CEA, CYFRA21-1, SCC, and proGRP in detecting lung cancer. Indian Journal of Cancer. 61(3). 509–515. 2 indexed citations
3.
Zhang, Xu‐Chao, Shan Xue, Yueliang Wang, et al.. (2023). SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer. Signal Transduction and Targeted Therapy. 8(1). 185–185. 8 indexed citations
4.
Zhang, Hongyan, Lifang Zhao, Xueqing Liu, et al.. (2022). Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer. Cell Cycle. 22(7). 841–857. 4 indexed citations
5.
Zhao, Lifang, Hongyan Zhang, Xueqing Liu, et al.. (2021). TGR5 deficiency activates antitumor immunity in non-small cell lung cancer via restraining M2 macrophage polarization. Acta Pharmaceutica Sinica B. 12(2). 787–800. 46 indexed citations
6.
Liu, Xueqing, Shan Xue, Jiabo Xu, et al.. (2021). Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China. Acta Pharmacologica Sinica. 43(1). 64–75. 33 indexed citations
7.
Du, Yong, Zhanjun Lu, Yi Ding, et al.. (2021). Hematological characteristics of patients with novel coronavirus pneumonia in intensive care unit. International Immunopharmacology. 97. 107697–107697.
8.
Jiang, Handong, et al.. (2021). [Interstitial lung disease revisited].. Zhonghua yixue zazhi. 101(20). 1453–1457. 1 indexed citations
9.
Cheng, Jiejun, Ying Zhang, Feng Zhang, et al.. (2020). The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC. Scientific Reports. 10(1). 3436–3436. 22 indexed citations
10.
Liu, Xueqing, Shan Xue, & Handong Jiang. (2019). CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways. Lung Cancer. PA4686–PA4686. 1 indexed citations
11.
You, Wenjie, Lijun Li, Xueqing Liu, et al.. (2019). Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy. Cancer Immunology Research. 7(6). 990–1000. 29 indexed citations
12.
Zhang, Sufen, Huifang Gao, Wanhong He, et al.. (2019). Hypermethylation of the PTTG1IP promoter leads to low expression in early‑stage non‑small cell lung cancer. Oncology Letters. 18(2). 1278–1286. 9 indexed citations
13.
Liu, Xueqing, Bi Chen, Wenjie You, et al.. (2017). The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer. Cancer Letters. 412. 194–207. 50 indexed citations
14.
You, Wenjie, Bi Chen, Xueqing Liu, et al.. (2017). Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Scientific Reports. 7(1). 591–591. 36 indexed citations
15.
16.
Chen, Bi, Wenjie You, Shan Xue, et al.. (2016). Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease. Journal of Thoracic Disease. 8(11). 3063–3074. 18 indexed citations
17.
Chen, Bi, Hourong Cai, Shan Xue, et al.. (2016). Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor‐dependent and independent pathways. Respirology. 21(6). 1075–1080. 41 indexed citations
18.
Jiang, Shan, Hong‐Chun Liu, Xianliang Xin, et al.. (2009). MS80, a novel sulfated polysaccharide, inhibits CD40-NF-κB pathway via targeting RIP2. Molecular and Cellular Biochemistry. 337(1-2). 277–285. 13 indexed citations
19.
Jiang, Handong & Huashi Guan. (2009). MS80, a novel sulfated oligosaccharide, inhibits pulmonary fibrosis by targeting TGF-β1 both in vitro and in vivo. Acta Pharmacologica Sinica. 30(7). 973–979. 20 indexed citations
20.
Zhai, Zhenguo, Handong Jiang, Xiaomei Qin, & Chen Wang. (2004). [Therapeutic effect and mechanism of sulfate polysaccharide of algae on lung cancer].. PubMed. 27(2). 97–100. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shan Xue Breakdown of academic impact, for papers by Yajuan Zheng Breakdown of academic impact, for papers by Ju Ock Kim Breakdown of academic impact, for papers by Elizabeth M. Park Breakdown of academic impact, for papers by Xinyu Shao Breakdown of academic impact, for papers by Xia Yang Breakdown of academic impact, for papers by Cheng‐Bei Zhou Breakdown of academic impact, for papers by Maysam Mard‐Soltani Breakdown of academic impact, for papers by Naoko Ishida Breakdown of academic impact, for papers by Praveen Neeli
Rankless by CCL
2026